Characteristics of the four bedaquiline-resistant Mycobacterium tuberculosis strains
| Previous treatments | M. tuberculosis strain | |||||
| Lineage | BDQ MIC mg·L−1 | atpE | rv0678 | MIRU-VNTR | ||
| H37Rv | 0.03 | WT | WT | |||
| Patient 1 | None | Delhi/CAS | 0.5 | WT | del gg 18-19 | 242 235 442 244 425 173 344 742 |
| Patient 2 | INH, RFB, EMB, PZA, CAP, MXF, LNZ and TER | S | 0.5 | WT | WT# | 233 353 212 434 215 133 336 A22 |
| Patient 3 | BDQ combined with PZA, ETH, CAP, CYC, PAS and AMC, but only PAS susceptible on DST | Beijing | 0.25 | WT | ins g140 | 244 233 352 644 425 153 353 823 |
| Patient 4 | INH, RIF, EMB, PZA, SM then KAN, MXF, ETH, CYC and PAS | Beijing | 0.015 | WT | WT | 244 233 352 644 425 173 353 623 |
| BDQ combined with EMB, PZA, AMK, ETH, LNZ, PAS, CFZ, PAS and IMP/AMC, but only PAS and AMK susceptible on DST | 0.25 | WT | M139T¶ | 244 233 352 644 425 173 353 623 | ||
BDQ: bedaquiline; MIC: minimal inhibitory concentration, MIRU-VNTR: mycobacterial interspersed repetitive units – variable number of tandem repeats; WT: wild-type; INH: isoniazid; RFB: rifabutin; EMB: ethambutol; PZA: pyrazinamide; CAP: capreomycin; MXF: moxifloxacin; LNZ: linezolid; TER: terizidone; ETH: ethionamide; CYC: cycloserine; PAS: para-aminosalicylic acid; AMC: amoxicillin-clavulanate; DST: drug susceptibility testing; RIF: rifampin; SM: streptomycin; KAN: kanamycin; AMK: amikacin; CFZ: clofazimine; IMP: imipenem. #: pepQ was sequenced and was also WT [7]; ¶: amino acid substitution in the Rv0678 protein.